PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmAla Biotech Holdings Inc. has secured a contract to supply LaNeo MDMA to a clinical trial at Harvard’s Maclean Hospital, aiming to improve patient lives by providing high-quality MDMA to U.S. researchers. The company also plans to attend the CPHI Conference in Milan to discuss potential distribution partnerships in Europe.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.